U.S. market Open. Closes in 5 hours 30 minutes

TELO | Telomir Pharmaceuticals, Inc. Common Stock Stock Financials Income Statements Annual

(Stock Exchange: NASDAQ)
*Sign In to persist settings
Financial Year End2023-12-312022-12-312021-12-31
RevenueN/AN/AN/A
Cost of Revenue3.94MN/AN/A
Gross Profit-3.94MN/AN/A
Operating Expenses3.94M854.15K138.13K
Selling, General & Admin600.19K20.94K11.64K
Research & Development1.57M833.21K126.49K
Other Operating ExpensesN/AN/AN/A
Operating Income-3.94M-854.15K-138.13K
Other Expenses / Income-9.13MN/AN/A
Before Tax Income-13.07M-854.15K-138.13K
Income Tax ExpensesN/A-854.14K-138.13K
Net Income-13.07M-854.15K-138.13K
Interest Expenses1.64MN/AN/A
Basic Shares Outstanding29.61M29.61M29.61M
Diluted Shares Outstanding29.61M29.61M29.61M
EBITDA-11.43M-854.15K-138.13K
EBITDA Margin0.00%0.00%0.00%
EBIT-11.43M-1.71M-276.26K
EBIT Margin0.00%0.00%0.00%
Financial Year End2023-12-312022-12-312021-12-31
An error has occurred. This application may no longer respond until reloaded. Reload 🗙